// App-Quantinova.ai

2514 : First-in-human trial of ONC201 in patients with refractory solid tumors.

Researchers

Presenter

  • Mark N. Stein

Principal Investigators

  • Nancy Chan

  • Ann W. Silk

  • Bruno Fang

  • Howard Kaufman

  • Bruce George Haffty

  • Tracie Saunders

  • Saltanat Najmi

  • Ling Zheng

  • Martin Stogniew

  • Joshua E. Allen

  • Wolfgang Oster

  • Joseph R. Bertino

  • Janice M. Mehnert

Medical Centers

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY

  • Regional Cancer Care Associates, Hackensack, NJ

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Rutgers, New Brunswick, NJ

  • Oncoceutics, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • TIC 10

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • NA

Study Id's

  • NCT02250781

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved